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Prostate cancer is now the most commonly diagnosed cancer in
males in the US, and is the second leading cause of cancer death
(Landis et al, 1998). Recent increases in detection rates, through
serum PSA testing and increased public awareness, have resulted
in larger numbers of patients being diagnosed, particularly in early
stages of the disease (Catalona et al, 1993). 
Markers are needed to help stratify the disease spectrum. Raised
PSA levels are not specific for malignant disease, and efficient
second line diagnostic methods are needed to deal with the increased
numbers of individuals being identified (Crawford et al, 1996). There
is also intense interest in the efficient detection of precursor lesions
such as high-grade PIN, which significantly increases the likelihood
of cancer development (Haggman et al, 1997). Following initial
diagnosis, inadequate tools and poor predictive methods handicap
prostate cancer management. Currently, microscopic analysis of
tissue by a pathologist is the established method (Gleason, 1993).
However, histopathology may be expensive and time consuming,
and is not of sufficient sensitivity to be predictive for the majority of
patients who fall into the intermediate grades (Menon, 1997). It is
hoped that advances in genetics and gene expression will allow more
accurate assessment of tumour aggressiveness, perhaps by use of a
panel of tumour biology markers reflecting proliferation, angiogen-
esis, loss of cellular adhesion, invasion, likelihood of metastasis and
avoidance of cell death (Hegarty et al, 1999). 
These problems may be addressed using a genomics-based
approach investigating global gene expression changes in clinical
samples using microarrays (Sagar, 1997; Burczak et al, 1998).
With suitable databases and bioinformatics tools, candidate genes
can be selected following in silico analysis for favourable tissue
distribution, secretion signals and other features, allowing empir-
ical design of microarrays for candidate marker screening. Gene
expression profiling is being increasingly used to analyse
hundreds or thousands of genes simultaneously in cancer cell lines
(Bertucci et al, 1999), and diseased and normal tissue (Zhang et al,
1997; Alon et al, 1999; Wang et al, 1999). Clustering analysis of
gene expression data can provide novel insights into disease, for
example molecular definition of subtypes of leukaemia, providing
a tool for an important diagnostic problem (Golub et al, 1999). 
To identify potential candidate prostate cancer markers we
assembled a custom microarray for analysis of prostate tissue,
biasing the clone choice on our array towards genes that are
expected to express at higher levels in cancer. The frequency of
clones in tissue-specific cDNA libraries in the proprietary Incyte
databases, which typically rank genes according to frequency in a
given library, was taken to reflect their true abundance in tissues.
Quantitative electronic subtraction of cDNA libraries (e.g. cancer
minus normal, late-stage minus early-stage) was used to increase
the odds of including relevant genes on the array, which could then
be checked by hybridization to diseased prostate cDNA. In
Identification of potential diagnostic markers of
prostate cancer and prostatic intraepithelial neoplasia
using cDNA microarray 
JH Bull1*, G Ellison1, A Patel3, G Muir2, M Walker4, M Underwood5, F Khan1 and L Paskins1†
1Enabling Science and Technology, AstraZeneca, Cheshire SK10 4TG, UK; 2Department of Urology, King’s College Hospital, Denmark Hill, London SE5 9RS,
UK; 3Department of Urology; 4Department of Histopathology, Imperial College of Science, Technology and Medicine at St. Mary’s Hospital, Praed Street, London
W2 1NY; 5Department of Urology, Queen Elizabeth Building, Glasgow Royal Infirmary, Glasgow, G31 2ER 
Summary The identification of novel genes or groups of genes expressed in prostate cancer may allow earlier diagnosis or more accurate
staging of the disease. We describe the assembly and use of a 1877-member microarray representing cDNA clones from a range of prostate
cancer stages and grades, precursor lesions and normal tissue. Using labelled cDNA from tumour samples obtained from TURP or radical
prostatectomy, analysis of expression patterns identified many up-regulated transcripts. Cell lines were found to over-express fewer genes
than diseased tissue samples. 17 known genes were found to over-express more than 4-fold in 4 or more cancers out of 15 cancers. Only 2
genes were over-expressed in 6 out of 15 cancers or more, whilst no genes were consistently found to be over-expressed in all cancer
samples. Novel prostate cancer associations for several well characterized genes or full length cDNAs were identified, including PLRP1,
JM27, human UbcM2, dynein light intermediate chain 2 and human homologue of rat sec61. Novel associations with high-grade PIN include:
breast carcinoma fatty acid synthase and cDNA DKFZp434B0335. We shortlist and discuss the most significant over-expressed genes in
prostate cancer and PIN, and highlight expression differences between malignant and benign samples. © 2001 Cancer Research Campaign
http://www.bjcancer.com
Keywords: array; carcinoma; PIN; BPH; benign prostatic hyperplasia; diagnosis 
1512
Received 4 August 2000 
Revised 22 February 2001 
Accepted 28 February 2001
Correspondence to: JH Bull 
British Journal of Cancer (2001) 84(11), 1512–1519
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.1816, available online at http://www.idealibrary.com on 
*Current address: CMC International, King Edward Street, Macclesfield, Cheshire
SK10 1AQ. 
†Current address: A1-Biotech UK, Anachem Ltd., Charles St., Luton, Bedfordshire,
LU2 0EB. 
http://www.bjcancer.comProstate cancer microarray 1513
British Journal of Cancer (2001) 84(11), 1512–1519 © 2001 Cancer Research Campaign
addition, in silico transcript imaging analysis was used to check
specificity against other tissue types. Known cancer and prostate-
associated genes were also included in the array. 
Although down-regulated genes are of great biological interest,
it is not convenient to assay their transcripts because biopsy or
other samples may contain normal tissue to varying degrees, and
disease tissue may form only a small part of the sample under
investigation. Therefore we set out to identify strongly over-
expressed genes, which may be detectable even in samples
containing a minority of affected tissue. This analysis of normal,
BPH, PIN and prostate cancer tissue provides a starting point for
further investigation of candidate marker genes for diagnosing,
staging and treating prostate cancer. 
MATERIALS AND METHODS 
Bioinformatics, databases and choice of cDNA clones 
Genes (or, in the case of unknown genes, clone clusters) of poten-
tial interest for microarray were selected either because of a
known association with prostate or cancer, or because of a relative
abundance in tumour libraries compared to normal prostate. For
the latter, manipulations were carried out using a proprietary data-
base (LifeSeq) provided by Incyte Pharmaceuticals (Palo Alto,
CA) which primarily contains grossly dissected and microdis-
sected prostate cDNA libraries. Several public domain libraries
including those from the Cancer Genome Anatomy Project are
also available in this database, including PIN libraries. Using
Incyte’s electronic tools for transcript imaging (virtual Northern
blot analysis) and library subtraction based on the BLAST algo-
rithm, the array was biased towards over-expressed genes which
might form useful diagnostic markers. This empirical approach
was complemented by inclusion of known prostate- and/or cancer-
associated genes from the literature. Physical clones for arraying
were chosen from a proprietary collection supplied by Incyte
Pharmaceuticals, many of which were sequence verified by Incyte.
Where available, 2 different clones per gene were used, typically
from the 3¢ region of the transcript. An additional set of 11 ‘house-
keeping’ genes was also included. A master list of clones was
maintained using Microsoft Excel software. 
The transcript imaging tool was used to interrogate the Incyte
Lifeseq Gold database for tissue distribution across 1113 cDNA
libraries. All sequence annotation, gene ID and transcript imaging
data presented in this paper was correct at the time of writing,
according to Incyte Lifeseq Gold version 5.1, February 2000
release. 
PCR and clone arraying 
Clones were assembled into 96-well microtitre plates containing
selective growth medium, grown overnight at 37˚C. The cDNA
inserts were amplified using universal primers for pINCY,
pSPORT and pBluescript (TTGGGTAACGCCAGGGTTTTC-
CCAGTCAC and CCCCAGGCTTTACACTTTATGCTTCCG-
GC) at 35 pmol 50 ml–1 reaction, in 96-well plates containing PCR
buffer (1.05 units Taq DNA polymerase, 20 mM Tris-HCl (pH
8.3), 50 mM KCl, 1.5 mM MgCl2 and 0.2 mM each dATP, dCTP,
dGTP and dTTP) (AB gene, Epsom, UK). PCR conditions were
94˚C, 2 min, followed by 35 cycles of 94˚C, 1 min, 60˚C, 1 min
and 72˚C 3 min followed by a final extension step of 72˚C for 10
min. PCR products were spotted onto Nytran + membrane
(Schleicher and Schuell, Keene, NH) using an automated robotic
system (Q-Bot, Genetix, Christchurch, UK) together with appro-
priate software. Null spots containing dye were used as a visual aid
to assess array quality and orientation. The DNA was denatured
using standard solutions and crosslinked to the membrane by ultra-
violet irradiation (Stratagene Stratalinker, La Jolla, CA). 
Prostate RNA, labelling and hybridization conditions 
Tumour samples were either from sections of radical prostat-
ectomy specimens, or tissue from transurethral resection, with
concurrent histopathological data. All clinical samples were
obtained with the approval of the ethics committee of the hospital
concerned. Tissue was flash frozen in liquid nitrogen and stored at
–70˚C until needed. Culture of prostate carcinoma cell lines was
performed under standard conditions. PC-3, DU 145 and LNCaP
cells were cultured in RPMI medium (Gibco, Paisley, UK), 5%
fetal calf serum (Gibco), 1% glutamate (Gibco). LNCaP cells were
initially cultured in this medium for 48 h, then medium was
replaced with charcoal-stripped medium, and cells incubated for a
further 48 h, followed by 48 h in fresh medium with or without a-
5-dihydrotestosterone. About 100 mg tissue or cells was used for
RNA extraction using Trizol (Gibco). RNA integrity was checked
by agarose gel electrophoresis. Normal prostate RNA was a
mixture from 20–30 accident victims with no diagnosable prostate
abnormality (Clontech, Palo Alto, CA). 15–20 mg total RNA was
treated with 10 units DNase I (RNase free) (Roche Molecular
Biochemicals, Lewes, UK) in a suitable volume, at room tempera-
ture for 15 min. EDTA was added to 2.5 mM, and the sample
heated to 65˚C for 10 min to stop the reaction. If necessary, at this
stage Microcon 30 columns (Amicon, Millipore, Bedford, UK)
were used to concentrate the sample. 15–20 mg RNA was allowed
to anneal to 0.5 mg of oligo (dT) primer 12–18 (Gibco) at 65–70˚C
for 10 minutes. First strand labelling was performed with 1st
Strand Labelling Buffer (Gibco) with the addition of dTTP, dATP
and dGTP at a final concentration of 0.5 mM and dCTP at 50 mM,
30 mCi a–33P dCTP (Amersham Pharmacia Biotech) and 40 units
RNase inhibitor (Roche). After 5 minutes at 42˚C, 200 units
Superscript II enzyme (Gibco) was added and the mix was incu-
bated at 42˚C for 1.5–2 hours. Unincorporated nucleotides were
removed by centrifugation through a GFX column (Amersham
Pharmacia Biotech) according to manufacturer’s guidelines. The
newly synthesized probe was denatured by boiling for 5 minutes
and stored on ice. Microarray filters were wetted in Church
hybridization solution (Church and Gilbert, 1984), and incubated
with a further ~5 ml of this solution in a cylindrical bottle rotated
in a hybridization oven at 65˚C for 4–5 h prior to the addition of
fresh solution and denatured probe, which was mixed by quickly
swirling. Hybridization was at 65˚C for ~ 16 h. Filters were washed
in Church wash solution (Church and Gilbert, 1984) at 65˚C for 
2 ´ 20 min. 
Image quantification and data analysis 
Filters were covered in clingfilm wrap and exposed to low-energy
phosphorimaging screens (Eastman Kodak, Rochester, NY) for
5–6 days, prior to phosphorimager scanning (Storm 830,
Molecular Dynamics, Sunnyvale CA). Images were manipulated
using ImageQuant software (Molecular Dynamics), and quantita-
tive data for spot intensity extracted using Incyte LifeArray soft-
ware, then exported to Microsoft Excel. The data were processed1514 JH Bull et al 
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in an Excel workbook sheet designed to (a) calculate a local back-
ground value for each of 96 small 7 ´ 7 grid areas on the array, and
discard data points within this area less than 2-fold this value, then
using this output (b) normalize by calculating a ratio for each value
against the mean value for housekeeping genes across the whole
array. Data could then be directly compared between filters. A
dataset for mean normal prostate was generated from 2 duplicate
array hybridization experiments of 2 independent mixed batches 
of normal prostate RNA. The 2 normal prostate RNA batches
comprised samples from 23 men (aged 23–64), and 47 men (aged
15–50), respectively, who were not diagnosed for prostate cancer
(Clontech). Typically, data from tumour samples was exported to a
second Excel workbook, and ratios generated against normal
values. Genes could then be ranked for level of over-expression,
and by assembling lists of ranked over-expressed genes, tumours
compared and data amalgamated. In some cases, data for genes in
the normal RNA were below the 2-fold background cut-off, and a
ratio could not be generated. These genes were classified on/off
(expressed in tumour, undetectable in normal). 
RESULTS 
Samples of prostatic material were collected from well character-
ized patients with either BPH (mean age (range) 75 (66–84) years),
PIN or prostate cancer (mean age (range) 68 (52–88) years)
(sample details are given in Table 1). Array data were normalized
to a representative selection of housekeeping genes, to allow
comparison of expression levels between hybridization experi-
ments. To generate a normal prostate dataset, mixed samples of
normal prostate from individuals (aged 15–64 years) with no
history of prostatic disease were used (Clontech), as normal
prostate material was not available. The mean of 2 hybridization
results for each of 2 different batches of normal prostate samples
was taken. No differences of greater than 2-fold were observed
between these pairs of normal prostate control filters. To evaluate
overexpression compared to normal prostate tissue, results from
cell culture, prostate cancer, PIN or BPH samples were ratioed
against the control normal prostate dataset, and genes with values
of greater than 1.5 ´ normal signal were considered to be over-
expressed. 
To evaluate overexpression of cancer relative to benign tumour,
a mean of 11 BPH samples (Table 1) was taken as the control
value, and results from cancer samples were ratioed against this.
Subsequently, all of the genes identified as overexpressed were
checked against the mean value for the set of 11 BPH samples. No
BPH sample deviated by 1.5 fold or more from the mean for any of
the genes of interest. 
Over-expressed genes are more common in prostate
tissue than cells 
The majority of genes found to be over-expressed in cancer, PIN
and BPH samples were expressed in normal tissue also. A variable
number of genes were expressed in diseased tissue but not detected
Table 1 Details of prostate samples used in this study 
Sample Origin/diagnosis Sample designation Gleason grade / other details Clinical stage 
A19 TURP/PIN PIN PIN2 on biopsy T0 
A39 TURP/PIN PIN 6 (in 3% chips) + PIN2 T0 
KC4 CaP CaP unknown unknown 
A49 radical/CaP CaP – early 4 + PIN2 T2 N0 
G53 TURP/CaP (20% of chips) CaP – early 2 + 2 T1b 
A53 radical/CaP CaP – early 5 + PIN2 T2 N0 
KC5 TURP/CaP in ?% chips CaP – early 6 T3 
A65 radical/CaP CaP – early 6 + PIN2 N0 
A48 radical/CaP CaP – early 6 N0 
A5 radical/CaP CaP – early 3 + 3 + PIN2 T2b N0 
A3 radical/CaP CaP – mid Left= 3+4: Right = PIN T3c N0 
KC1 TURP/CaP in only 10% chips CaP – mid 8 unknown 
A46 TURP/CaP CaP – late 9 NX 
A63L radical/CaP CaP – late 9 + PIN2 N1 
A63R radical/CaP CaP – late 9 + PIN2 N1 
A2 TURP/CaP CaP – late 9 unknown 
KC3 TURP/CaP in 90% chips CaP – late 9 received post-hormonal therapy unknown 
KC2 TURP/CaP in nearly all chips CaP – late 5 + 4 T4 
KB1 TURP/BPH BPH N/A T0 
KB11 TURP/BPH BPH N/A T0 
KB2 TURP/BPH BPH N/A T0 
KB3 TURP/BPH BPH N/A T0 
KB4 TURP/BPH BPH N/A T0 
KB5 TURP/BPH BPH N/A T0 
KB6 TURP/BPH BPH N/A T0 
KB7 TURP/BPH BPH N/A T0 
KB8 TURP/BPH BPH N/A T0 
KB9 TURP/BPH BPH N/A T0 
KB10 TURP/BPH/prostatitis BPH/prostatitis N/A T0 
Range of samples used in this study showing histological data and tumour stage where known/appropriate. The Gleason grading system is widely used as it
relates differentiation of cancer, and correlates with prognosis. The scale used is 2–10 (Gleason, 1992). Tumour stage details are according to the TNM
classification system: T0 indicates no evidence of primary tumour; T1–T2 tumours are confined to the prostate, T3 tumours extend through the prostatic
capsule, T4 indicates invasion of adjacent structures, N0 indicates no regional lymph node metastasis; N1 indicates limited lymph node involvement (full details
of the TNM system are in Jones and Smith, 1994). Prostate cancer microarray 1515
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in normal tissue, but these genes were always in a minority
compared to genes detected in normal but over-expressed in
tumour (Figure 1). In contrast, prostate cancer cell lines displayed
a high proportion of genes whose expression was not detected in
normal prostate. Compared to normal prostate, LNCaP cells 
over-expressed roughly twice as many genes as DU-145, PC3 and
LNCaP cells deprived of androgen (Figure 1 and Table 2).
However, samples of prostate containing or comprising PIN, BPH
or cancer consistently displayed much higher levels of global
over-expression than the cell systems, typically in the range
200–600 genes (Figure 1). There is no strong difference in
numbers of over-expressed genes between 2 PIN, 11 BPH and 16
cancer tissue samples (Table 2). 
Over-expressed genes in cancer 
Table 3 lists 17 genes most commonly over-expressed in prostate
cancer samples compared to normal prostate samples. In addition
Table 3 Over-expressed genes in prostate cancer 
Gene identity/hit gi number Hits Mean ratio/normal Putative function/ References 
cancer association
CC chemokine gene cluster g3719360 5 6.9 putative unknown gene in cluster Nomiyama et al, 1999 
cystatin SA-I g337751 5 6.8 thiol protease inhibitor AI-Hashim et al, 1988 
autoantigen calreticulin g179881 4 7.5 calcium binding protein Rokeach et al, 1991 
pancreatic lipase related protein PLRP1 g187229 5 6.6 unknown association Giller et al, 1992 
coagulation factor V g182411 6 6.3 blood clotting Jenny et al, 1987 
FYN binding protein g2232150 4 5.4 T-cell function da Silva et al, 1997 
JM27 g3114821 4 6.8 soares placenta unpublished 
mouse ubiquitin-conjugating enzyme UbcM2 g5114058 4 5.9 CD34+ cell unpublished 
PA26-T1 nuclear protein g1329 4 5.5 non p53-induced gene transcript in  Buckbinder et al, 1994 
human Saos-2 osteosarcoma cells
cytochrome P1-450 g181275 5 5.9 protection against chemical  Jaiswal et al, 1985, 
carcinogenesis Talalay, 1989 
nucleolin g189305 5 5.5 nucleolar phosphoprotein involved  Srivastava et al, 1990 
in the synthesis and maturation of 
ribosomes
p78 cell cycle regulated factor g2384716 4 7.1 proliferation-related nucleolar  Ren et al, 1998
protein found at much higher levels 
in most human malignant tumors
p97 g1857236 6 20.7 translational regulator, thought to  Imataka et al, 1997 
be general repressor
dynein light intermediate chain 2 g2665835 4 5.3 Cytoplasmic dynein is a  unpublished
multi-subunit complex involved in 
retrograde organelle transport and 
some aspects of mitosis
Rat sec61 homolog mRNA g5106794 4 4.3 protein transport in NB4 cell line unpublished 
cDNA DKFZp564C0362 g5262486 4 6.6 novel mRNA from fetal brain unpublished 
SRF accesory protein 1A (SAP-1) s22 g429185 4 6.5 binds to serum response factor  Dalton and Treisman, 
1992 DNA sequence. Also homology to 1992
cadherin-10
Genes over-expressed in 4 or more cancer samples from a total of 15. Figures are mean fold signal relative to mean normal prostate (where normal prostate
value was below the 2-fold background threshold, no normal value was available, so the figure given is fold signal over 2-fold background – see section 2.4).
The mean value is calculated for a single clone spot per filter (that which gave the highest number of positives across the samples).
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Figure 1 Genes over-expressed in various sample types compared to
normal prostate. The graph plots the total number of over-expressed genes
for each prostate sample (1–33); cell lines (1–4); LNCaP, LNCaP treated by
androgen deprivation, PC-3, DU 145; PIN (5,6), TURP chips containing BPH
(7–17), TURP chips containing BPH and cancer (18–20), TURP chips
containing cancer, and radical prostatectomy segments (20–33) 
Table 2 Levels of overexpression in sample types
Cell lines PIN TURP/BPH TURP/some Cancer
cancer
Samples tested 4 2 11 3 13 
Mean (SD)  75.2 381.5 315.5 715.7 456.3
over-expressed (37.2) (57.3) (155.5) (371.4) (255.8)
genes
Mean numbers of genes over-expressed in different types of prostate
material, relative to normal prostate tissue. 1516 JH Bull et al 
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to several blood cell-related protein genes which may be associ-
ated with host response to tumour presence (e.g. FYN binding
protein and human UbcM2 genes) the list contains several genes
and full length cDNAs that are likely to be expressed in the
prostate tissue and may constitute specific markers of cancer.
These include the strongly over-expressed p97 and p78 genes. A
novel association with prostate cancer is apparent for the full-
length cDNA DFKZp564CO362, which encodes an uncharacter-
ized protein. In addition, this is the first report of a prostate cancer
association for the genes PLRP1, JM27, human UbcM2, dynein
light intermediate chain 2 and human homologue of rat sec61. 
Following collation of these data, the transcript imaging tool
was used in the Incyte Lifeseq Gold database to check tissue distri-
bution across 1113 cDNA libraries. Examples of genes for which
this data reflected and supported array data are CC chemokine and
dynein light intermediate chain 2. CC chemokine tended to be
represented in prostate cancer and PIN libraries, but not normal
prostate or other tissue types. Dynein light intermediate chain 2
was present in many tissue types, but within the set of prostate
libraries tended to be over-represented in cancer. For other genes,
transcript imaging analysis gave mixed results which did not
always reflect array data: JM27 was present almost exclusively in
prostate libraries, but in both normal and disease types; in contrast
FYN binding protein and cytochrome p-1450 were not present in
any prostate libraries. Their presence on the array was presumably
fortuitously due to reallocation to new gene clusters by Incyte
following our initial clone selection at the array construction stage
(see Discussion). The rest of the markers characterized by the
microarray results appeared in many tissue libraries and had no
obvious prostate cancer association as indicated by transcript
imaging data. 
Over-expressed genes in high grade PIN 
Table 4 lists 9 genes most commonly over-expressed in high-grade
PIN relative to normal prostate. Again, host response genes feature
(e.g.  SRp40–1 and  CD–24), but are outnumbered by genes of
likely prostatic origin, e.g. k-ras. Novel associations with prostate
cancer include breast carcinoma fatty acid synthase and the full
length cDNA DKFZp434B0335. Transcript imaging analysis
showed wide tissue library distribution for all these genes, but an
association with prostate cancer was particularly strong for fatty
acid synthase and TAT interactive protein genes. 
Over-expression in cancer compared to benign tumour 
6 transcripts were over-expressed in at least 5 out of 13 prostate
cancer samples compared to mean BPH transcript level (Table 5).
Table 4 Genes over-expressed in PIN 
Gene identity gi number PIN 19 PIN 39 Function/association References 
DKFZp434B0335 g5911996 7.12 6.83 adult testis unpublished 
IGFBP 4 g33265191 5.99 5.61 bone cells Zazzi et al, 1998 
splicing factor SRp40-1 g1049079 6.25 6.52 T-cell activation Screaton et al, 1995 
DiGeorge syndrome critical region, centromeric end g137775 4.94 3.21 unknown Gong et al, 1996 
Human lupus p70 (Ku) autoantigen g178649 4.95 7.54 unknown Reeves and Sthoeger, 1989 
fatty acid synthase g91531 5.72 3.85 breast carcinoma unpublished 
TAT interactive protein g1657981 4.6 6.26 interacts with HIV protein Kamine et al, 1996 
k-ras g1815608 4.02 2.05 proto-oncogene Kahn et al, 1987 
CD-24 signal transducer g500848 5.02 6.47 B-cell activation Kay, 1991 
Genes over-expressed more than 2-fold, in common between 2 PIN samples (figures given are ratios against normal prostate; representative data are given for
one of 2 identical spots on the array).
Table 5 Genes over-expressed in prostate cancer relative to BPH 
Gene identity gi number Hits CaP/normal ratio Function References 
G(i) protein alpha-subunit g31743 6 2.2 Increased levels associated with  Didsbury et al, 1987 
monocyte differentiation.
CC chemokine g3719360 7 3.8 Nomiyama et al, 1999 
metallopeptidase PRSM1 g1354930 8 2.8 Growth factor activation and  Scott et al, 1996 
extracellular matrix synthesis 
and degradation. Found in 
cultured osteosarcoma cells
DKFZp586D091 g4884127 5 not detected  Adult uterus unpublished 
in normal or BPH
laminin B2 chain g186962 5 not detected  Epithelial cell basement
in normal or BPH membrane Kallunki et al, 1991 
repressor of estrogen receptor
activity (REA) g5020252 5 not detected in  May play an important  Montano et al, 1999 
normal or BPH role in determining the 
sensitivity of oestrogen
target cells in BC
Markers increased by more than 1.5-fold in 5 or more cancer samples out of 15, relative to mean value for BPH. CaP/normal values are mean expression 
levels for those samples in which signal >1.5 ´ normal, or >1.5 ´ mean of 13 BPH samples. 3 genes were found to be expressed in cancer but not detected in
BPH. Prostate cancer microarray 1517
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None of these 6 genes was expressed by more than 1.5 ´ mean
BPH level in any of the 11 BPH samples listed in Table 1. Only
one of these genes, CC Chemokine, features in the set of genes
identified as over-expressed in 4 or more cancers compared to
normal prostate (Table 3). Levels of over-expression in cancer
relative to BPH are much lower than cancer relative to normal
prostate (compare Tables 3 and 5), suggesting that most genes
over-expressed in cancer are also over-expressed in BPH, and so
may be of limited use in a molecular diagnostic situation necessi-
tating differentiation between the 2 disease states. However, we
detected 3 genes in 5/13 cancers which were not detected in any of
11 BPH samples used in this study. These are DKFZp586D091 (a
full length cDNA encoding a protein of unknown function),
laminin B2 chain, and a repressor of oestrogen activity (REA).
Transcript imaging supported this data: DKFZp586D091 was
represented in only a few libraries per tissue type with the excep-
tion of nervous system, and at high frequency in only one prostate
(tumour) library; REA was more ubiquitously and frequently
represented, but was common in prostate tumour libraries and rare
in normal and BPH. These 3 genes were not co-expressed in the
same cancers (data not shown), but a combination of them could
form the basis of a diagnostic test capable of detecting cancer in a
prostate sample containing or comprising mostly BPH cells. 
Relative levels of gene expression from array data 
The data presented in Tables 3, 4 and 5 are in the form of ratios of
transcript levels in malignant or pre-malignant disease compared
to normal or benign disease. In order to compare relative levels of
expression for genes of interest (including genes which were not
detected in normal tissue, and for which an accurate over-
expression ratio could not be generated) it was necessary to refer
to normalized filter data on a sample to sample basis. Table 6
allows comparison of expression levels for many of the genes
featured in Tables 3–5. For example, it can be seen that levels of
JM27 and  CC chemokine (possible discriminatory marker for
cancer versus normal cells – Table 3) transcripts are approximately
50% that of laminin B2 (a possible discriminatory marker for
cancer versus BPH cells – Table 5) and 35% that of prostate-
specific antigen (PSA). These results will form the benchmark for
further investigations with RT-PCR. 
DISCUSSION 
We are interested in using molecular criteria to distinguish
between different disease states within the prostate. Accordingly,
we have focused on genes which exhibited higher than normal
levels of expression in cancer and PIN, as indicated by tissue
distribution data in silico. Following array analysis, our aim was to
shortlist genes that could enable molecular diagnosis of cancer
and/or PIN despite the quantities of normal and BPH tissue which
may be present in a biopsy sample. The results we present form the
starting point for further studies using accurate RNA quantitation
methods such as RT-PCR (e.g. Bieche et al, 1999). 
Our data support the notion that cell lines may be of limited
value in the identification of novel markers and drug targets by
transcript profiling, because of the limited number of differentially
expressed genes. LNCaP cells over-expressed roughly twice as
many genes as the hormone-independent, advanced cancer cell
line models PC3 and DU-145. Nevertheless, the proportion of
gene transcripts undetected in normal tissue, but present in cancer
cells, is higher for the cell lines studied than for diseased tissue.
Tissue samples exhibited much wider global gene expression
activity, with many more transcripts identified as over-expressed.
However, this conclusion has several caveats: firstly our array was
biased toward differential expression between disease states and
normal tissue, rather than towards cell lines. Second, experimental
factors such as variation in probe labelling can account for differ-
ences in the number of over-expressed genes detected. Thirdly,
many of the genes we have identified are associated with host
immune response (see Tables 3 and 4) and may not be cancer-
specific. The variable proportion of stromal and epithelial cells
present in prostatic tissue samples present less of a problem,
because all data presented here are compared to mean values for
normal prostate tissue or BPH. 
We chose to analyse clinical material from TURP and radical
prostatectomy specimens rather than needle biopsies. This has the
advantage that more material is available, and can be taken from
parts of the prostate with macroscopically visible morphological
features, adjacent to tissue for which pathology details is available.
We believe this approach will anticipate findings in biopsy
samples, but lessens the problems associated with heterogeneity in
the diseased gland. Ordinarily, 6 needle biopsies taken at different
angles are needed to give a good chance of detecting cancer or PIN
(Jarmulowicz, 1999). Extra samples can be taken for study, but
Table 6 Comparative levels of gene expression in prostate cancer 
Gene identity gi number Mean
expression 
level 
TAT interactive protein g1657981 15.9 
myosin light chain kinase g1262344 4.12 
ribosomal protein L35 g34200 3.4 
histone H 3.3 g761715 3.37 
p97 g1857236 2.49 
ribosomal protein L18 g337492 2.21 
fibroblast collagenase inhibitor g182482 2.03 
p97 g1857236 1.99 
PSA g35720 1.95 
metallopeptidase PRSM1 g1354930 1.86 
laminin B2 g186962 1.53 
steroid 5 alpha reductase g338468 1.47 
Novel human gene mapping to chromosome 1 g5834563 1.35 
p27 g2982672 1.34 
proteasome subunit HC5 g220025 1.32 
coagulation factor V g182411 1.32 
transforming growth factor alpha g37089 1.32 
prostatic acid phosphatase g439664 1.31 
bcl-2 g179370 1.18 
ribosomal protein L35 g407422 1.16 
metalloproteinase inhibitor g608128 1.14 
nucleolin gene g189305 0.91 
cystatin SA-I g337751 0.9 
CC chemokine g3719360 0.81 
ublquitin activating enzyme E1 g340071 0.77 
JM27 g3114821 0.71 
putative protein kinase regulator g3641524 0.58 
pre-mRNA splicing factor (PRP17) g3123907 0.41 
Relative levels of gene expression in cancer samples, showing details for a
selection of gene transcripts detected in 4 or more /15 prostate tumours.
Those not detected in normal prostate (i.e. signals < 2´ background on
control filters) are listed in bold. Mean expression levels are in arbitrary units. 1518 JH Bull et al 
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these are also subject to sampling error and may increase the risk
of morbidity in the patient. Our approach has yielded a small
number of potential markers which can be justifiably progressed
into assessment on biopsy samples in a more convenient, higher
throughput format such as RT-PCR. 
To keep the physical size of the filter (and therefore the amount
of starting mRNA needed) to a minimum, we wished to keep array
size within a reasonable limit of 2000 genes. The physical size of
the array (~7 ´ 11 cm) allowed ease of handling, and accommo-
dated a simple first-strand cDNA-labelling method. 
Clone sequences were screened prior to arraying using the
Incyte sequence databases wherever possible to ensure that Alu or
other repeat sequences were not present. Cot-1 DNA was used in
some experiments to address problems of repeat sequence
hybridization and cross-hybridization. However, comparison of
datasets showed this was not a significant problem (data not
shown). Certain I.M.A.G.E. clones used were from the Cancer
Genome Anatomy Project cDNA libraries Pr1–10 (details are
found at http://www.ncbi.nlm.nih.gov/ncicgap/). Whilst these
libraries offer the advantage of being derived from microdissected
PIN or cancer lesions, clones are made from amplified second
strand cDNA, and clone frequency may not reflect true mRNA
abundance to the same extent as the Incyte cDNA libraries, gener-
ally made by cloning of first strand cDNA. We biased the clone
choice on our array towards genes which are expected to express at
higher level in cancer, taking clone frequency in cDNA libraries as
an indication of their true abundance, but this potential pitfall was
kept in mind. 
A period of over one year elapsed between the time of clone
choice for microarray assembly, and collation of results for this
paper, at which time all sequences were checked in the relevant
Incyte database for current gene identity. Some clones had been
reassigned to a new gene cluster, based on BLAST homology,
during this period. This is a result of updating of sequence data
from Incyte and new data of public origin which also is assimilated
into the Incyte Lifeseq Gold database. Thus, though most array
genes were chosen purely on the basis of library frequency, the
current database release does not give the same results for some
genes. This, combined with an unknown component due to cross-
hybridization between closely related cDNA species, probably
accounts for the disparity often seen between array data and tran-
script imaging results. This disparity cautions against inferred
associations between genes on the basis of library frequency alone,
as has been reported by other groups (e.g. Walker et al, 1999), and
strongly suggests that verification of potential markers with highly
specific approach is necessary. This work is in progress using RT-
PCR methodology. 
Assessing the range of gene expression in normal prostate tissue
was hindered by the lack of availability of this tissue due to ethical
constraints. Mixtures of mRNA from various individuals (as
supplied commercially) were the only available source of normal
prostate tissue for this study. However, the data from paired filters
for 2 different batches of this material was checked for variation of
the genes characterized in this study, with the result that over-
expression of >1.5 fold above mean was not seen for any gene of
interest. 
At present, the most specific molecular marker for PIN is
absence of GST P1 expression in tumour cells (Brooks et al,
1998). Because PIN cells and normal or BPH cells are often found
in the same sample, it is not feasible to test for absence of expres-
sion without associated morphological data from microscopy 
(e.g. via immunohistochemistry). Our shortlist of candidate PIN-
associated genes requires verification from more samples, RT-PCR
and in situ hybridization, but may lead to a solution to this
problem. 
There was no obvious difference between global gene expres-
sion profiles of cancer and BPH. It was interesting that most of the
genes which were over-expressed in cancer were also over-
expressed in BPH (data not shown), perhaps reflecting the cellular
proliferation which occurs in both states. However, 6 genes were
identified as being potential discriminatory markers between BPH
and cancer, as detailed in section 3.4. In particular, 3 genes,
DFKZp586D091, laminin B2 and REA were detected at high levels
in cancer tissue but not detected in either BPH or normal prostate.
Further study of the expression of these genes by RT-PCR and in
situ hybridization could lead to a rapid molecular diagnostic
capable of discriminating cancer from BPH, which avoids exten-
sive histological analysis. 
Defining genes that are differentially expressed in normal, BPH,
PIN and cancer could lead to molecular testing of biopsies or TUR
chips for malignancy. In addition, some of these genes have the
potential to be therapeutic drug targets. Further, markers of disease
progression in organ-confined cancer patients are needed to plan
appropriate therapy, as many of these patients undergo radical
prostatectomy without being cured. RT-PCR-based tests in a rapid
format could be used during surgery to provide information on
likelihood of metastasis. Also, patients could benefit from early
therapy if there were molecular indications that metastases were
present. Although microarray analysis is not ideal for diagnostic
applications, markers thus identified may be validated by further
studies, and a panel of markers capable of distinguishing disease
states could result. In addition, candidates for serum or immuno-
histochemical tests can be identified. 
In summary we have identified novel associations in prostate
cancer for several well characterized genes or full length cDNAs
including PLRP1, JM27, human UbcM2, dynein light intermediate
chain 2 and human homologue of rat sec61 and also novel associ-
ations with high-grade PIN, which include: breast carcinoma fatty
acid synthase and cDNA DKFZp434B0335. These genes may
prove advantageous in defining prostatic proliferative disease
states and may have important diagnostic and therapeutic potential
in prostate cancer. 
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